AbbVie

AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas including immunology, oncology and neuroscience – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.

1 North Waukegan Road
North Chicago, IL 60064

Visit website

Stock Symbol: ABBV
Stock Exchange: NYSE

Together, we break through.

Our principles are at the Heart of our Company. Operating as one AbbVie team, we care deeply for our patients, their families, our employees, and our communities. We strive to always do the right thing, pursuing the highest standards in quality, compliance, safety, and performance. In everything we do, we invest and innovate relentlessly to tackle unmet needs, creating new medicines and healthcare approaches for a healthier world.

How we work with each other and achieve results matters. That’s why we’ve been honored to receive some of the most prestigious ratings and recognitions in the industry, including being named on more than 40 Great Place to Work and Top Employer lists and FORTUNE “100 Best Companies to Work For.”

Click here to learn more about our principles.

NEWS

Drug Development

AbbVie Eyes Regulatory Approval for Atogepant After Positive Phase III Migraine Study

Atogepant, an oral CGRP receptor antagonist, is an experimental migraine treatment AbbVie gained through its acquisition of Allergan.

July 30, 2020

3 min read

Alex Keown

BioCapital

Clinical Catch-Up: July 20-24

It was a busy week for clinical trial news, with some very important early-stage trial data for various COVID-19 vaccines. Here’s a look.

July 24, 2020

8 min read

Mark Terry

Drug Development

AbbVie’s Rinvoq Hits the Mark in Pivotal Phase III Dermatitis Trial

AbbVie announced that its Rinvoq (upadacitinib) as a monotherapy hit both primary and all secondary endpoints in the second Phase III trial, Measure Up 2, in patients with moderate to severe atopic dermatitis.

July 22, 2020

2 min read

Mark Terry

FDA

Allergan/AbbVie’s Macular Degeneration Drug Abicipar Pegol Rejected by FDA

The U.S. Food and Drug Administration issued a Complete Response Letter, a rejection, of Allergan’s Biologics License Application for Abicipar pegol for neovascular age-related macular degeneration.

June 26, 2020

3 min read

Mark Terry

Business

Sosei Heptares and AbbVie Partner on Inflammatory and Autoimmune Diseases

The companies will work to discover, develop and commercialize novel therapies that modulate G protein-coupled receptor (GPCR) targets that AbbVie selects.

June 25, 2020

3 min read

Mark Terry

BioMidwest

AbbVie and Alpine Immune Ink $865 Million Deal to License Drug for Lupus and Other Inflammatory Diseases

Under the terms of the deal, AbbVie is paying Alpine an upfront payment of $60 million for rights to ALPN-101, a first-in-class dual CD28/ICOS costimulation antagonist.

June 18, 2020

3 min read

Mark Terry

BioMidwest

AbbVie’s Venclexta and Chemo Combination Decreases Death by 34% in AML

AbbVie reported positive results from the VIALE-A clinical trial of Venclexta plus azacytidine in previously untreated acute myeloid leukemia (AML) patients who were ineligible for intensive chemotherapy.

June 15, 2020

2 min read

Mark Terry

Business

AbbVie Plunks Down $750 Million Upfront for Cancer Therapy Deal with Genmab

The collaboration will focus on the development of three of Genmab’s bispecific antibodies and will also involve a discovery research collaboration for future antibody therapeutics for cancer.

June 10, 2020

3 min read

Alex Keown